CER Daily Newsfeed

Value Viewpoint: November 1, 2024

(11/1, Kimberly Westrich, LinkedIn) comments “...Speaking of the [National Alliance of Healthcare Purchaser Coalitions], if you’re attending the upcoming Annual Forum, please join NPC at: Monday, November 18: I will be leading the ‘Engaging Employers to Action: Strategies to Address PBM Misalignment’ workshop and discussion...Tuesday, November 19: John O'Brien will join a panel discussion on ‘Unlocking Value: Building Trusted Tools to Assess High-Value Care’...” Full

Risankizumab Effectively Clears Psoriasis in Indirect Comparison to Deucravacitinib

(11/4, Connor Iapoce, HCPLive) reports “Risankizumab outperformed deucravacitinib in achieving PASI 75/90/100 and improving quality of life in moderate-to-severe PsO patients. The study used MAIC methodology to compare risankizumab and deucravacitinib, addressing the lack of head-to-head trials.” Full

Certain Diabetes Drugs Linked to Lower Risk of Kidney Stones and Gout

(11/1, British Medical Journal, Medical Xpress) reports “...As well as treating type 2 diabetes, trials have shown that SGLT-2 inhibitors can also lower the risk of heart failure and kidney disease, but their effect on recurrent kidney stones and gout flare-ups is still uncertain. To explore this further, researchers set out to compare the effects of SGLT-2 inhibitors on risk of recurrent kidney stones and gout with two other groups of diabetes drugs known as GLP-1 receptor agonists and DPP-4 inhibitors.” Full

Podcast: Drug Pricing and the 2024 Presidential Election

(11/1, Ayla Ellison, Zoey Becker, Fierce Pharma) reports “...In this week's episode of ‘The Top Line,’ Fierce Pharma's Zoey Becker chats with John Barkett, managing director of BRG's healthcare transactions and strategy practice and former senior policy advisor for healthcare delivery system reform on the White House Domestic Policy Council, about what we can expect from each candidate's potential presidency and how the Inflation Reduction Act could play a pivotal role.” Full